ConductScience.org, home

Paper20948438

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Louis CU and 14 others. J Immunother, 2010. Cited by 187 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. Papers, record 20948438. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20948438

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
PubMed
Journal
J Immunother
PubMed
Year
2010
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
187
iCite
Relative citation ratio, by iCite
4.28
iCite
Revised in PubMed
2022-03-10
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Louis CUChrystal U
2Straathof KKarin
3Bollard CMCatherine M
4Ennamuri SSravya
5Gerken CClaudia
6Lopez TTTeresita T
7Huls MHM Helen
8Sheehan AAndrea
9Wu MFMeng-Fen
10Liu HHao
11Gee AAdrian
12Brenner MKMalcolm K
13Rooney CMCliona M
14Heslop HEHelen E
15Gottschalk SStephen

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
Herpesvirus 4, HumanMajor topic
Immunotherapy, AdoptiveMajor topic
Nasopharyngeal NeoplasmsMajor topic
T-Lymphocytes, CytotoxicMajor topic
Adolescent
Adult
Antigens, Viral
Cell Proliferation
Child
Disease Progression
Disease-Free Survival
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Prognosis
Treatment Outcome

Source PubMed

Download CSV of topics

Grants10

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K01 RR000188NCRR NIH HHSUnited StatesK01RR000188PubMed and NIHNIH RePORTER
T32 DK64717NIDDK NIH HHSUnited StatesT32DK064717PubMed and NIHNIH RePORTER
M01 RR000188NCRR NIH HHSUnited StatesK01RR000188PubMed and NIHNIH RePORTER
K12 CA09043306NCI NIH HHSUnited StatesK12CA090433PubMed and NIHNIH RePORTER
K12 CA090433NCI NIH HHSUnited StatesK12CA090433PubMed and NIHNIH RePORTER
P01 CA094237NCI NIH HHSUnited StatesP01CA094237PubMed and NIHNIH RePORTER
P01 CA94237NCI NIH HHSUnited StatesP01CA094237PubMed and NIHNIH RePORTER
RR00188NCRR NIH HHSUnited StatesK01RR000188PubMed and NIHNIH RePORTER
T32 DK064717NIDDK NIH HHSUnited StatesT32DK064717PubMed and NIHNIH RePORTER
M01RR000188NIHNIH RePORTER

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00609219T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPCBackgroundClinicalTrials.gov
NCT02421640Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPCBackgroundClinicalTrials.gov
NCT03044743PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesBackgroundClinicalTrials.gov

Download CSV of trials

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111018123Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.Annu Rev Microbiol2000https://conductscience.org/library/papers/11018123PubMed
219211798Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19211798PubMed
318354418Adoptive cell transfer: a clinical path to effective cancer immunotherapy.Nat Rev Cancer2008https://conductscience.org/library/papers/18354418PubMed
415611290Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.J Exp Med2004https://conductscience.org/library/papers/15611290PubMed
511912175Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.Cancer Res2002https://conductscience.org/library/papers/11912175PubMed
612427970Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/12427970PubMed
715809453Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.J Clin Oncol2005https://conductscience.org/library/papers/15809453PubMed
817609424Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.Blood2007https://conductscience.org/library/papers/17609424PubMed
910655437
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst2000https://conductscience.org/library/papers/10655437PubMed
1012411306Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.Blood2003https://conductscience.org/library/papers/12411306PubMed
1118213730Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.Head Neck2008https://conductscience.org/library/papers/18213730PubMed
1216951192Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.Cancer Res2006https://conductscience.org/library/papers/16951192PubMed
1317909810Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.Cancer Chemother Pharmacol2008https://conductscience.org/library/papers/17909810PubMed
1412181249Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.Ann Oncol2002https://conductscience.org/library/papers/12181249PubMed
159716582Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.Blood1998https://conductscience.org/library/papers/9716582PubMed
1612167421A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.Oral Oncol2002https://conductscience.org/library/papers/12167421PubMed
1715612023Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.Cancer2005https://conductscience.org/library/papers/15612023PubMed
1811159505An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.Blood2001https://conductscience.org/library/papers/11159505PubMed
1916148164Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.J Immunol2005https://conductscience.org/library/papers/16148164PubMed
2020222940Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome.Radiat Oncol2010https://conductscience.org/library/papers/20222940PubMed

See all 40 referencesDownload CSV of references

Cited by126

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.

PMIDTitleJournalYearIn PapersSource
42752793Nasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and management.Mol Biomed2026https://conductscience.org/library/papers/42752793PubMed
42700448CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.Rev Med Virol2026https://conductscience.org/library/papers/42700448PubMed
42695022Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review.Lancet Reg Health West Pac2026https://conductscience.org/library/papers/42695022PubMed
42510669Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications.Biology (Basel)2026https://conductscience.org/library/papers/42510669PubMed
42389513Epstein-Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics.Front Immunol2026https://conductscience.org/library/papers/42389513PubMed
42195319Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives.Life (Basel)2026https://conductscience.org/library/papers/42195319PubMed
42193922Natural Killer (NK) Cells in Tumor Immunity: Limitations and Therapeutic Potential with a Focus on Nasopharyngeal Carcinoma and Comparison with T-Cell-Based Therapies.Cells2026https://conductscience.org/library/papers/42193922PubMed
42180045Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges.Front Oncol2026https://conductscience.org/library/papers/42180045PubMed
41750326Nasopharyngeal Carcinoma at the Virology Precision Oncology Nexus: Decoding Molecular Alterations for Early Intervention and Therapeutic Innovation.Biomolecules2026https://conductscience.org/library/papers/41750326PubMed
40844293Adoptive T-cell therapy for virus-associated diseases.Clin Microbiol Rev2025https://conductscience.org/library/papers/40844293PubMed
40563634The Role of Viruses in the Glioma Tumor Microenvironment: Immunosuppressors or Primers for Anti-Tumor Immunity?Cancers (Basel)2025https://conductscience.org/library/papers/40563634PubMed
40401927Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions.J Cell Mol Med2025https://conductscience.org/library/papers/40401927PubMed
40191756The role and mechanism of aerobic glycolysis in nasopharyngeal carcinoma.PeerJ2025https://conductscience.org/library/papers/40191756PubMed
39450176Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies.Front Immunol2024https://conductscience.org/library/papers/39450176PubMed
39338919Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review.Pathogens2024https://conductscience.org/library/papers/39338919PubMed
38888489Characterization of unique pattern of immune cell profile in patients with nasopharyngeal carcinoma through flow cytometry and machine learning.J Cell Mol Med2024https://conductscience.org/library/papers/38888489PubMed
38815238Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.Blood Adv2024https://conductscience.org/library/papers/38815238PubMed
38755255Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.NPJ Precis Oncol2024https://conductscience.org/library/papers/38755255PubMed
38023360Precision drugs for recurrent or metastatic nasopharyngeal carcinoma (Review).Exp Ther Med2023https://conductscience.org/library/papers/38023360PubMed
37932756Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.J Transl Med2023https://conductscience.org/library/papers/37932756PubMed

See all 126 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20948438

GET https://conductscience.org/api/papers/v1/20948438/references?page=2